INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT03272464
Phase
PHASE1
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Trametinib — DRUG
    Trametinib may work by binding to your cancer cells to inhibit the cancer cells' signals to decrease cell growth.
  • Dabrafenib — DRUG
    Dabrafenib may work by stopping your cancer cells from duplicating.
  • INCB039110 — DRUG
    Itacitinib may work by stopping your tumor cells from living and growing.

Study Details

This research study is studying a combination of drugs as a possible treatment for BRAF-mutant melanoma. The drugs involved in this study are: * Itacitinib (INCB039110) * Dabrafenib * Trametinib

Key Dates

Start date
May 29, 2019
Status verified
Nov 2022
Primary completion
Jul 24, 2019
Completion
Dec 27, 2019

Study Design

Enrollment
1 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Trametinib + Dabrafenib + INCB039110
    * Dabrafenib is administered orally every 12 hours * Trametinib is administered orally once a day * INCB039110 is administered orally once a day

Primary Outcome Measure

Maximum Tolerated Dose [ Time Frame: Approximately 2 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts General HospitalBostonMassachusetts02214-

Find similar trials in Boston, MA

By condition
Melanoma
By specialty
OncologySkin cancerDermatology
By research site
Massachusetts General Hospital· Boston, MA

Related Studies